SCHEMBL6282382

SCHEMBL6282382

COc1ccc(NC(=O)Nc2ncc(C(C)C)s2)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 7/20 0.54
CCNE1 P24864 6/20 0.54
CDK5 Q00535 6/20 0.54
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CCNT1 O60563 1/20 0.44
CDK1 P06493 1/20 0.44
CDK4 P11802 1/20 0.44
CCNB1 P14635 1/20 0.44
CCNA2 P20248 1/20 0.44
CCND1 P24385 1/20 0.44
CDK7 P50613 1/20 0.44
CDK9 P50750 1/20 0.44
CCNH P51946 1/20 0.44
MNAT1 P51948 1/20 0.44
CDK5R1 Q15078 1/20 0.44
LPAR1 Q92633 2/20 0.43
MEN1 O00255 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285364 0.85 MAPT (0.56) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL6283718 0.81 CDK2 (0.72) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL6288089 0.81 CDK2 (0.68) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL6287790 0.80 KMT2A (0.56) CDK2CCNE1CDK5ALDH1A1MEN1
SCHEMBL6279306 0.80 CCNE1 (0.70) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL5835450 0.77 NPC1 (0.58) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL6286038 0.77 SMN1; SMN2 (0.65) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL6371368 0.76 RAB9A (0.53) MEN1NPC1RAB9AKMT2AMAPT
SCHEMBL6285565 0.76 CDK2 (0.57) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2
SCHEMBL5835686 0.76 MAPT (0.55) CDK2CCNE1CDK5ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CDK2 3/4885CCNE1 83/4885CDK5 129/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CDK2 3/4885CCNE1 83/4885CDK5 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.